Prophylaxis for Human Immunodeficiency Virus–Related Pneumocystis carinii Pneumonia

Authors:
  • SGSue J. Goldie
    Sue J. Goldie
  • JKJonathan E. Kaplan
    Jonathan E. Kaplan
  • ELElena Losina
    Elena Losina
  • MWMilton C. Weinstein
    Milton C. Weinstein
  • APA. David Paltiel
    A. David Paltiel
  • GSGeorge R. Seage
    George R. Seage
  • DCDonald E. Craven
    Donald E. Craven
  • AKApril D. Kimmel
    April D. Kimmel
  • HZHong Zhang
    Hong Zhang
  • CCCalvin J. Cohen
    Calvin J. Cohen
  • KFKenneth A. Freedberg
    Kenneth A. Freedberg

Abstract
PNEUMOCYSTIS CARINII pneumonia (PCP) is the most common serious opportunistic infection among patients infected with human immunodeficiency virus (HIV) in the United States.1-3 Initiating PCP prophylaxis at a CD4 cell count less than 200/µL has been the standard of care for the past decade.4,5 In the past few years, however, there has been a dramatic reduction in the rates of opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy (HAART), prompting reassessment of the role of prophylaxis.6-24 Several recent publications25-28 suggest a convergence of opinion in favor of discontinuing PCP prophylaxis in patients whose CD4 cell counts have increased to greater than 200/µL with HAART.

This publication has 1 reference indexed in Scilit: